Paul Emery, MA, MD, FRCP arc Professor of Rheumatology
Head of the Academic Unit of Musculoskeletal Disease
University of Leeds
Leeds Teaching Hospitals Trust
Leeds, United Kingdom Prof Emery has nothing to disclose.
Josef S. Smolen, MD Professor of Medicine
Division of Rheumatology
Medical University of Vienna
Hietzing Hospital
Vienna, Austria Prof Smolen has been on the advisory board for scientific information of Abbott Laboratories, AstraZeneca, Bristol-Myers Squibb Company, Centocor, Inc., F. Hoffman LaRoche Ltd, Schering-Plough Corporation, UCB S.A., and Wyeth. He has also received grant/research support from Abbott Laboratories, Bristol-Myers Squibb Company, F. Hoffman LaRoche Ltd, Schering-Plough Corporation, UCB S.A., and Wyeth.
Roy Fleischmann, MD Professor of Medicine
University of Texas Southwestern Medical Center
Dallas, United States Dr. Fleischmann has been a consultant and received clinical grants from
UCB S.A.
Topics
• Data Demonstrate 1-Year Safety and Efficacy for New TNF Inhibitor Plus MTX
• Certolizumab Pegol Plus MTX Associated With Early Response
• Certolizumab Pegol Monotherapy Demonstrates Efficacy as Compared With Placebo
